
Somalogic Expands Proteomics Testing Platform to Encompass 11,000 Proteins
11-1-23 (by: Scott Gleason) SomaLogic, a specialty CRO focused on proteomic testing has announced the launch of the SomaScan 11K Platform. This new platform offers 11,000 total protein measurements, making it the most comprehensive proteomics offering available on the market. Previously the company had offered a platform to analyze 7,000 proteins. The new offering now covers half of the human proteome.
The new platform is designed to enhance drug research. Proteins represent more than 90% of all known drug targets, and this broader view of the human proteome, facilitated by SomaLogic’s 11K platform, unlocks new opportunities for additional biological discoveries. This high-plex platform utilizes aptamers, which are short single stranded DNA molecules that can bind to a specific protein, setting it apart from traditional antibody-based platforms and ensuring lower coefficients of variation (CV), typically ranging from 10% to 20%. The greater accuracy allows better analysis with small sample sizes.
When speaking about the new offering, Adam Taich, CEO of SomaLogic stated, “Our scientists focused on maintaining the platform’s reproducibility, sensitivity, and specificity across a 10-log dynamic range with every expansion of our SomaScan menu size.”
The SomaScan 11K Platform is already in operation at SomaLogic’s assay services lab in Boulder, Colorado. Furthermore, selected authorized sites have started utilizing this expanded platform, with more sites expected to be online in the fourth quarter of this year.